Skip to content
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Neurology

Building a Foundation: What is NIID?

At a Glance

NIID is a rare, progressive disorder linked to an expanded repeated DNA segment in the NOTCH2NLC gene. It can affect the brain, peripheral nerves, and automatic body functions, while diagnosis may combine genetic testing, MRI, and a skin biopsy.

Neuronal Intranuclear Inclusion Disease (NIID) is a rare, progressive condition that affects the nervous system and multiple organs throughout the body [1]. For many years, NIID was difficult to identify because its symptoms—such as memory loss, tremors, and balance issues—can look like many other neurological diseases [2]. However, recent breakthroughs in genetics and imaging have made it much easier for doctors to recognize and diagnose this condition earlier than ever before [3].

Understanding Rarity and Recognition

NIID is officially classified as a rare disease [4]. Because it is so rare, there is no single global number that tells us exactly how many people have it. However, researchers are finding that it may be more common than previously thought, especially among people of East Asian ancestry [5][6].

The “rarity” of NIID is partly because it was historically underdiagnosed (meaning people had the disease but were told they had something else, like Alzheimer’s or Parkinson’s) [4]. In some specialized East Asian clinic cohorts evaluating specific unexplained brain changes, NIID accounted for nearly 18% of cases [7]. As genetic testing becomes more widely available, more families are finally receiving an accurate answer for their symptoms.

The Genetic Cause: The NOTCH2NLC Gene

The primary driver of NIID is a specific change in a gene called NOTCH2NLC [1]. Most people have a small number of “GGC” repeats in a specific section of this gene. In people with NIID, this section expands, repeating the GGC sequence dozens or even hundreds of times [8].

Research suggests this expansion may cause two main problems inside your cells:

  1. RNA Toxicity: The cell produces “messengers” (RNA) from the expanded gene that can get stuck in clumps, trapping other important proteins the cell needs to function [1][9].
  2. PolyG Protein Production: Even though this part of the gene isn’t supposed to make protein, the expansion may trick the cell into making a toxic protein called polyG [1]. These proteins are sticky and clump together, disrupting the cell’s internal machinery [10].

The Pathology: “Glassy” Inclusions

A supportive hallmark of NIID is the presence of intranuclear inclusions [11]. These are tiny, round clumps of protein that form inside the nucleus (the control center) of the cell [12].

Under a microscope, these inclusions have specific characteristics:

  • Eosinophilic: They appear bright or pale pink when stained with certain medical dyes [12].
  • Hyaline: They have a smooth, “glassy” or transparent appearance [13].
  • Ubiquitin and p62 Positive: These are “tagging” proteins the cell uses to mark trash for disposal. Because the cell is trying (and failing) to get rid of the toxic clumps, the inclusions are covered in these markers, which helps pathologists identify them [11][14].

Because these inclusions show up in many parts of the body—not just the brain—doctors can often confirm a diagnosis using a skin biopsy [11]. They look for these glassy pink circles in the sweat glands, fat cells, or connective tissues of the skin [15].

How NIID Progresses

NIID is a multisystem disease, meaning it can affect the brain, the nerves in your limbs, and the autonomic nervous system (which controls things you don’t think about, like digestion and blood pressure) [2]. While it is a progressive condition, the speed and way it develops can vary greatly between individuals, even within the same family [16].

Current care focuses on supportive management, which means a team of doctors works together to treat your specific symptoms and improve your quality of life [17]. Early diagnosis is a vital step because it allows you and your medical team to create a plan that addresses your unique needs and avoids treatments that might not be helpful for this specific condition [18].

Common questions in this guide

What is neuronal intranuclear inclusion disease?
NIID is a rare, progressive disorder that affects the nervous system and can involve multiple organs. It may cause memory problems, tremors, balance difficulties, confusion, and problems with automatic body functions such as digestion or blood pressure.
What genetic change is linked to NIID?
NIID is most strongly linked to an expansion of GGC repeats in the NOTCH2NLC gene. The expansion may produce abnormal RNA clumps and a toxic protein called polyG, which can disrupt normal cell function.
What symptoms can NIID cause?
NIID can cause memory loss, tremors, balance problems, and episodes of confusion. Because it may affect the autonomic nervous system, people can also have symptoms involving digestion or blood pressure, and some report unusual episodes of fever or vomiting.
How do doctors diagnose NIID?
Doctors may combine a NOTCH2NLC genetic test with brain MRI and an assessment of symptoms. A skin biopsy can show characteristic glassy inclusions in sweat glands, fat cells, or connective tissue, while p62 and ubiquitin staining can support the finding.
What does a skin biopsy show in NIID?
A skin biopsy may reveal small, round, glassy protein clumps inside cell nuclei in structures such as sweat glands, fat cells, or connective tissue. These inclusions often stain positive for p62 and ubiquitin, markers that help pathologists recognize them.
How is NIID treated, and how does it progress?
NIID is currently managed with supportive, symptom-focused care rather than one treatment that reverses the disease. A care team may address neurological and autonomic problems, and the rate and pattern of progression can differ greatly from person to person.

Get notified when new evidence is published on Neuronal intranuclear inclusion disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (18)
  1. 1

    Upstream open reading frame with NOTCH2NLC GGC expansion generates polyglycine aggregates and disrupts nucleocytoplasmic transport: implications for polyglycine diseases.

    Zhong S, Lian Y, Luo W, et al.

    Acta neuropathologica 2021; (142(6)):1003-1023 doi:10.1007/s00401-021-02375-3.

    PMID: 34694469
  2. 2

    Expanding the clinical spectrum of adult-onset neuronal intranuclear inclusion disease.

    Cao Y, Wu J, Yue Y, et al.

    Acta neurologica Belgica 2022; (122(3)):647-658 doi:10.1007/s13760-021-01622-4.

    PMID: 33625684
  3. 3

    Clinicopathological features of adult-onset neuronal intranuclear inclusion disease.

    Sone J, Mori K, Inagaki T, et al.

    Brain : a journal of neurology 2016; (139(Pt 12)):3170-3186 doi:10.1093/brain/aww249.

    PMID: 27797808
  4. 4

    Unraveling rare form of adult-onset NIID by characteristic brain MRI features: A single-center retrospective review.

    Li F, Wang Q, Zhu Y, et al.

    Frontiers in neurology 2022; (13()):1085283 doi:10.3389/fneur.2022.1085283.

    PMID: 36588885
  5. 5

    NOTCH2NLC-related disorders: the widening spectrum and genotype-phenotype correlation.

    Fan Y, Xu Y, Shi C

    Journal of medical genetics 2022; (59(1)):1-9 doi:10.1136/jmedgenet-2021-107883.

    PMID: 34675123
  6. 6

    Neuronal intranuclear inclusion disease: recognition and update.

    Lu X, Hong D

    Journal of neural transmission (Vienna, Austria : 1996) 2021; (128(3)):295-303 doi:10.1007/s00702-021-02313-3.

    PMID: 33599827
  7. 7

    Prevalence and Characterization of NOTCH2NLC GGC Repeat Expansions in Koreans: From a Hospital Cohort Analysis to a Population-Wide Study.

    Lee S, Yoon JG, Hong J, et al.

    Neurology. Genetics 2024; (10(3)):e200147 doi:10.1212/NXG.0000000000200147.

    PMID: 38779172
  8. 8

    A comprehensive study of clinicopathological and genetic features of neuronal intranuclear inclusion disease.

    Liu M, Gao Y, Yuan Y, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2023; (44(10)):3545-3556 doi:10.1007/s10072-023-06845-2.

    PMID: 37184590
  9. 9

    Genetic origin of sporadic cases and RNA toxicity in neuronal intranuclear inclusion disease.

    Deng J, Zhou B, Yu J, et al.

    Journal of medical genetics 2022; (59(5)):462-469 doi:10.1136/jmedgenet-2020-107649.

    PMID: 33766934
  10. 10

    Microglia contribute to polyG-dependent neurodegeneration in neuronal intranuclear inclusion disease.

    Zhong S, Lian Y, Zhou B, et al.

    Acta neuropathologica 2024; (148(1)):21 doi:10.1007/s00401-024-02776-0.

    PMID: 39150562
  11. 11

    The Value of NOTCH2NLC Gene Detection and Skin Biopsy in the Diagnosis of Neuronal Intranuclear Inclusion Disease.

    Pang J, Yang J, Yuan Y, et al.

    Frontiers in neurology 2021; (12()):624321 doi:10.3389/fneur.2021.624321.

    PMID: 34017298
  12. 12

    [Neuronal intranuclear inclusion disease: a clinicopathological study of two cases].

    Wu N, Wang X, Zhang RS, et al.

    Zhonghua bing li xue za zhi = Chinese journal of pathology 2020; (49(10)):1031-1035 doi:10.3760/cma.j.cn112151-20200428-00347.

    PMID: 32992418
  13. 13

    Adult-onset neuronal intranuclear inclusion disease presenting with typical MRI changes.

    Han X, Han M, Liu N, et al.

    Brain and behavior 2019; (9(12)):e01477 doi:10.1002/brb3.1477.

    PMID: 31749292
  14. 14

    Re-evaluating archival specimens as a pathologic diagnostic resource for neuronal intranuclear inclusion disease.

    Lian Y, Zhong S, Liang J, et al.

    American journal of clinical pathology 2026; (165(5)) doi:10.1093/ajcp/aqag041.

    PMID: 42177789
  15. 15

    Genetic and Pathological Characteristic Patterns of a Family With Neuronal Intranuclear Inclusion Disease.

    Zhang S, Gong Q, Wu D, et al.

    Journal of neuropathology and experimental neurology 2020; (79(12)):1293-1302 doi:10.1093/jnen/nlaa142.

    PMID: 33271601
  16. 16

    Clinical features of NOTCH2NLC-related neuronal intranuclear inclusion disease.

    Tian Y, Zhou L, Gao J, et al.

    Journal of neurology, neurosurgery, and psychiatry 2022; (93(12)):1289-1298 doi:10.1136/jnnp-2022-329772.

    PMID: 36150844
  17. 17

    Levodopa intolerance as a potential clinical red flag for neuronal intranuclear inclusion disease (NIID) in atypical parkinsonism: a case report.

    Zang P, Liu Y, Hao Y

    BMC neurology 2026; (26(1)).

    PMID: 41634634
  18. 18

    Multiple reversible encephalitic attacks: a rare manifestation of neuronal intranuclear inclusion disease.

    Li M, Li K, Li X, et al.

    BMC neurology 2020; (20(1)):125 doi:10.1186/s12883-020-01712-5.

    PMID: 32268889

This overview is for educational purposes and does not replace medical advice. A neurologist, genetic counselor, or pathologist can help interpret your symptoms, test results, and biopsy findings.